The one-day 'Amsterdam Session' aimed to facilitate open discussions between strategic leaders working within the pharmaceutical industry as well as independent experts working to improve access to medicine. The springboard for discussions was the Foundation’s recent 10-Year Analysis of pharmaceutical companies’ activities to improve access to medicine in low- and middle-income countries.
The 'Amsterdam Sessions’ are a series of roundtables convened by the Foundation to address key topics and challenges in access to medicine, with conversations taking place under the Chatham House Rule. Each Session focuses on a specific area where healthcare companies have a clear role to play, and is joined by leading experts from industry, governments, the investor community, and NGOs.
The Foundation convenes these sessions to identify practical and concrete actions for stakeholders to take. Insights and conclusions have been captured in a meeting report.
Inside the report
This four-page report summarises the day’s discussions, organised along the following themes:
What does the next decade look like for access to medicine?
Access planning during R&D: what are the key factors?
Affordability and commercial sustainability: a path to effective strategies